Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» breast cancer
breast cancer
Olema Oncology previews Phase III trial plans for dual-mechanism SERD in breast cancer
Clinical Trials Arena
Fri, 09/23/22 - 10:57 am
Olema Oncology
SERD
breast cancer
ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing
Fierce Pharma
Wed, 09/7/22 - 11:59 pm
Gilead Sciences
Trodelvy
ESMO
HR-positive HER-negative breast cancer
breast cancer
Dizal reports positive Phase I data for breast cancer therapy
Clinical Trials Arena
Tue, 09/6/22 - 10:37 am
Dizal Pharmaceutical
clinical trials
breast cancer
HER2-positive metastatic breast cancer
DZD1516
As Sanofi's SERD falls, Menarini’s advances with EU review
Fierce Biotech
Fri, 08/19/22 - 10:42 am
Sanofi
Menarini
Europe
SERD
breast cancer
elacstrant
Sanofi scraps oral SERD strategy after 2nd failure in breast cancer
Fierce Biotech
Wed, 08/17/22 - 10:50 am
Sanofi
SERD
breast cancer
clinical trials
FDA approves AstraZeneca, Daiichi drug in breast cancer first
BioPharma Dive
Sun, 08/7/22 - 11:24 pm
AstraZeneca
Daiichi Sankyo
breast cancer
Enhertu
FDA
HER2-low breast cancer
AstraZeneca wins two recommendations, one priority review
Morningstar
Mon, 07/25/22 - 10:54 am
AstraZeneca
Europe
Daiichi Sankyo
Enhertu
breast cancer
Ultomiris
Tezspire
CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt
Fierce Biotech
Thu, 07/14/22 - 10:58 am
CytomX Therapeutics
breast cancer
layoffs
praluzatamab ravtansine
The Cytomx paradox
EP Vantage
Mon, 07/11/22 - 10:21 am
CytomX
breast cancer
CX-2009
CytomX halts lead program and will seek a partner as breast cancer drug disappoints
Endpoints
Thu, 07/7/22 - 10:26 am
clinical trials
CytomX
breast cancer
praluzatamab ravtansine
This Cancer Drug's News Could Mean Another Blockbuster for AstraZeneca
Motley Fool
Tue, 06/14/22 - 11:42 am
AstraZeneca
breast cancer
Enhertu
ASCO22: Enhertu aces key HER2-low test in breast cancer
Pharmaforum
Mon, 06/6/22 - 09:43 am
ASCO 2022
AstraZeneca
Daiichi Sankyo
Enhertu
HER2-low breast cancer
breast cancer
ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt
Fierce Pharma
Sun, 06/5/22 - 11:42 pm
Gilead Sciences
Trodelvy
breast cancer
ASCO 2022
ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?
Fierce Pharma
Sun, 06/5/22 - 11:40 pm
ASCO 2022
Pfizer
Ibrance
HR-positive
HER2-negative breast cancer
breast cancer
clinical trials
At ESMO, three studies show promise of antibody-drug conjugates in breast cancer
Pharmaforum
Mon, 05/30/22 - 10:23 am
ESMO
breast cancer
antibody-drug conjugate
AstraZeneca
Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Fierce Pharma
Mon, 05/23/22 - 06:46 pm
Seagen
Tukysa
breast cancer
colorectal cancer
clinical trials
FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer
Contract Pharma
Thu, 05/5/22 - 10:40 am
AstraZeneca
Daiichi Sankyo
Enhertu
FDA
HER2+ breast cancer
breast cancer
FDA clears wearable 3D ultrasound for breast imaging
MedCity News
Tue, 05/3/22 - 10:32 pm
devices
Medtech
FDA
iSono Health
ultrasound
breast imaging
breast cancer
Roche’s oral SERD giredestrant fails breast cancer trial
Pharmaforum
Mon, 04/25/22 - 10:48 am
Roche
breast cancer
SERD
Giredestrant
clinical trials
Gilead's Immunomedics settles over-hyped ASCO data mishap for $4M
Endpoints
Mon, 04/18/22 - 10:44 am
Immunomedics
Gilead Sciences
ASCO
breast cancer
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »